Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1614 of 5804
-
Biopsy after ablation: a new way to catch hidden cancer?
Knowledge-focused Recruiting nowThis study will see whether collecting and analyzing needle biopsy samples from cancer liver metastases after a tumor ablation procedure will be able to identify cancer cells that are still alive. The results of these biopsies could help determine the next treatment for your canc…
Phase: PHASE2, PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New hope for kids with heart valve disease: mini mechanical valve under study
Disease control OngoingThis PAS is an observational, non-randomized, multi-center, single arm, clinical study to evaluate long term safety and effectiveness of the SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve (15 AHPJ-505) as a replacement device for pediatric patients w…
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New breast cancer drug shows promise in slowing tumor growth
Disease control TerminatedPrimary Objective: To determine whether amcenestrant per overall survival (os) improves progression free survival (PFS) when compared with an endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer Secondary Object…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control TerminatedThis is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immune cells armed to fight pancreatic cancer: a new hope?
Disease control OngoingThe purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Targeted drug pemigatinib tested in tumors with FGFR mutations – trial stopped early
Disease control TerminatedThe purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New MRI-Guided radiation aims to spare cancer patients from chronic dry mouth
Symptom relief OngoingRadiotherapy is the main treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Many advances regarding tumor control and patient survival have been made over the past decades. However, treatment-induced toxicity remains a crucial problem, leading to…
Phase: NA • Sponsor: Panagiotis Balermpas • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
New drug duo shows promise for tough colorectal cancer
Disease control OngoingThis phase II trial studies the side effects and how well niraparib and panitumumab work in treating patients with colorectal cancer that has spread to other places in the body. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. I…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New combo therapy aims to fight inoperable uterine cancer
Disease control OngoingPatients with inoperable endometrial cancer have limited treatment options. PD-L1 expression is common in endometrial cancers and RT induces tumor and systemic changes that induce the immune system. The purpose of this trial is to evaluate anti-PD-1/PD-L1 axis therapy in conjunct…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could less surgery be better for prostate cancer recurrence?
Disease control Recruiting nowSignificant advances in molecular nuclear medicine imaging in prostate cancer have been achieved in recent years. In particular, the introduction of prostate-specific membrane antigen (PSMA) -based tracers has significantly influenced diagnostic imaging of prostate. If cancer rec…
Phase: NA • Sponsor: Martini-Klinik am UKE GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Common diabetes drug may boost survival in septic shock
Knowledge-focused CompletedSeptic shock is a major complication of sepsis and is one of the leading causes of admission to intensive care unit (ICU) as well as a major contributor to global mortality, accounting for one in five deaths worldwide and approximately 11 million deaths annually. There is around …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New sphincter implant shows promise for Post-Prostate surgery leakage
Disease control CompletedTo evaluate the AMS 800 Artificial Urinary Sphincter (AUS) in men with primary stress urinary incontinence as measured by pad weight tests.
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug FS1502 targets Hard-to-Treat HER2 cancers in early trial
Disease control CompletedThe study comprises two phases: Phase 1a and Phase 1b. The purpose of the study is to observe the safety, tolerability and efficacy of FS-1502.
Phase: PHASE1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:21 UTC
-
Can a zap to the ear tame sepsis?
Disease control Recruiting nowSepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. It is the most expensive healthcare condition to treat in United States and has a mortality rate of nearly 30%. It is widely known that exaggerated inflammation and imbalance between…
Phase: NA • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can intensive hand therapy help babies recover from stroke?
Disease control CompletedThis is a Phase III clinical trial to compare the efficacy of two dosages of a new infant rehabilitation protocol - I-ACQUIRE - to usual and customary forms of infant rehabilitation in infants who experienced Perinatal Arterial Stroke (PAS).
Phase: PHASE3 • Sponsor: Virginia Polytechnic Institute and State University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Blood thinner warfarin under scrutiny for dialysis patients with irregular heartbeat
Disease control Recruiting nowThe study aims to evaluate the appropriateness of initiating oral anticoagulation for stroke risk reduction in dialysis populations with atrial fibrillation. Specifically, the study will assess the overall safety, tolerability, and efficacy of initiating treatment with Warfarin i…
Phase: PHASE4 • Sponsor: Nicholas Carlson • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New antibiotic shows promise for kids with tough infections
Disease control CompletedThe primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected gram-negative bacterial infection. Participants are expected to require hos…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail aims to boost stem cell harvest in myeloma patients
Disease control Recruiting nowThis phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Phase: PHASE1 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug shows promise in reversing lung damage from severe asthma
Disease control OngoingThe purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroi…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Deep gene search aims to uncover why some young people get cancer
Knowledge-focused Recruiting now5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transm…
Phase: NA • Sponsor: Centre Georges Francois Leclerc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC